Cipla receives final approval for generic version of Gilead Sciences Incs Letairis AmbrisentanTabs 5mg and 10mg Kumar Jeetendra | April 30, 2019 Mumbai, India; April 30, 2019: – Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg & 10mg from the United States Food and Drug Administration (US FDA). rnrn rn Cipla’s Ambrisentan Tablets 5mg & 10mg …
Lupin in alliance with Natco receives FDA approval for Bosentan Tablets Kumar Jeetendra | April 30, 2019 Mumbai, Baltimore, April 30, 2019: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Actelion Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg. rnrn Lupin …
